In a groundbreaking development, doctors and researchers at Tata Institute in Mumbai have unveiled a promising drug that could revolutionize cancer treatment by preventing its recurrence and significantly reducing associated side effects.

This innovative tablet, a result of over a decade of extensive research and testing, is not only touted to prevent cancer recurrence but also claims to decrease side effects from treatments like radiation and chemotherapy by a remarkable 50%. The findings are based on trials conducted on mice, sharing a significant genetic resemblance to humans.

Dr. Rajendra Badve, a senior cancer surgeon at Tata Memorial Hospital and a key figure in the research group, elaborated on the discovery process. He explained that the tablets, named pro-oxidant tablets containing resveratrol and copper (R+Cu), were administered to rats in response to the potential risk of cancerous transformation posed by chromatin particles released during cancer cell death.

"When taken orally, these tablets release oxygen radicals in the stomach, quickly entering the bloodstream. This process prevents the release of cell-free chromatin particles in circulation and inhibits the movement of cancer cells, a process called metastases," Dr. Badve stated.

The researchers assert that R+Cu tablets not only hinder the spread of cancer but also mitigate the toxicity associated with chemotherapy, a crucial advancement in cancer treatment.

Referred to as the "Magic of R+Cu," this discovery is expected to cut treatment side effects by approximately 50% and demonstrate a 30% efficacy in preventing cancer recurrence. The tablet is anticipated to be effective against cancers affecting the pancreas, lungs, and oral regions.

Awaiting approval from the Food Safety and Standards Authority of India (FSSAI), the tablet is projected to hit the market by June-July. Dr. Badve assured that if approved, the cost of the tablet would be significantly lower than the development expenses, potentially less than Rs 100.

While the tablet's impact on side effects has been tested on both rats and humans, prevention tests have been conducted only on rats. Human trials are anticipated to take a minimum of five years to complete.

Dr. Badve emphasized the significance of this breakthrough, stating, "There were challenges during the research, many felt it was a waste of time and money. But today, everyone is happy and excited. It is a big success." The potential of this drug offers a ray of hope in advancing cancer treatment and enhancing the quality of life for patients worldwide.